<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499196</url>
  </required_header>
  <id_info>
    <org_study_id>LD2020</org_study_id>
    <nct_id>NCT04499196</nct_id>
  </id_info>
  <brief_title>Glucocorticoids and Pulmonary Hypertension</brief_title>
  <official_title>Prospective Study of Glucocorticoids as a Mechanism to Treat Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever&#xD;
      expanding body of knowledge indicates the important contribution of inflammation to&#xD;
      pathogenesis and successful treatment with glucocorticoids. Over the last several years we&#xD;
      have utilized steroids in patients with severe pulmonary hypertension as part of a treatment&#xD;
      regimen. These basic science studies possibly identifies a biochemical etiology for the&#xD;
      development of disease and may also be impacted by the administration of steroids.&#xD;
      Additionally, there is a commercially available assay which tests for all of the above&#xD;
      molecules.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Echo estimation of RV pressure</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pulmonary Hypertension Due to Lung Diseases and Hypoxia</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Bronchopulmonary Dysplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GlucoCorticoid</intervention_name>
    <description>Administering glucocorticoid</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        neonates with BPD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  premature, BPD, &gt;36 wga&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  poor ventilation/oxygenation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manish Aggarwal, MD</last_name>
    <phone>314-273-8329</phone>
    <email>maggarwal@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald M Grady, MD</last_name>
    <phone>314-454-6095</phone>
    <email>rmgrady@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Aggarwal, MD</last_name>
      <phone>314-454-6095</phone>
      <email>maggarwal@wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994 Feb;144(2):275-85.</citation>
    <PMID>7508683</PMID>
  </reference>
  <reference>
    <citation>Perros F, Dorfm√ºller P, Montani D, Hammad H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S, Cohen-Kaminsky S, Humbert M, Lambrecht BN. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Feb 1;185(3):311-21. doi: 10.1164/rccm.201105-0927OC. Epub 2011 Nov 22.</citation>
    <PMID>22108206</PMID>
  </reference>
  <reference>
    <citation>Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Nov 1;186(9):897-908. doi: 10.1164/rccm.201202-0335OC. Epub 2012 Sep 6.</citation>
    <PMID>22955318</PMID>
  </reference>
  <reference>
    <citation>Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32. doi: 10.1152/ajplung.00217.2009. Epub 2009 Sep 11. Review.</citation>
    <PMID>19748998</PMID>
  </reference>
  <reference>
    <citation>Langleben D, Reid LM. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy. Lab Invest. 1985 Mar;52(3):298-303.</citation>
    <PMID>3156262</PMID>
  </reference>
  <reference>
    <citation>Wang W, Wang YL, Chen XY, Li YT, Hao W, Jin YP, Han B. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep. 2011 Jun;38(5):3277-84. doi: 10.1007/s11033-010-0390-x. Epub 2011 Mar 23.</citation>
    <PMID>21431360</PMID>
  </reference>
  <reference>
    <citation>Ogawa A, Nakamura K, Mizoguchi H, Fujii N, Fujio H, Kusano KF, Ohe T, Ito H. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011 Jan 1;183(1):139-40.</citation>
    <PMID>21193794</PMID>
  </reference>
  <reference>
    <citation>Ogawa A, Nakamura K, Matsubara H, Fujio H, Ikeda T, Kobayashi K, Miyazaki I, Asanuma M, Miyaji K, Miura D, Kusano KF, Date H, Ohe T. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005 Sep 20;112(12):1806-12. Epub 2005 Sep 12. Erratum in: Circulation. 2006 Apr 18;113(15):e713.</citation>
    <PMID>16157769</PMID>
  </reference>
  <reference>
    <citation>Aggarwal M, Grady RM. Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication. Cardiol Young. 2017 Sep;27(7):1410-1412. doi: 10.1017/S1047951117000464. Epub 2017 May 16.</citation>
    <PMID>28506331</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

